Radiosynoviorthesis for Osteoarthritis in People and What It Has to Do with Synovetin OA in Dogs

Osteoarthritis (OA) isn’t just “worn-out cartilage.” For many people, a major source of pain and swelling comes from an inflamed synovium, which is the lining of the joint. When this synovitis becomes chronic, a joint can remain persistently painful even after standard treatments such as weight management, physical therapy, oral or topical medications, and conventional joint injections. This is where radiosynoviorthesis (RSO) has found a role in human medicine as a targeted, intra-articular approach aimed specifically at calming synovial inflammation.

Radiosynoviorthesis, also called radiation synovectomy or radiosynovectomy, is a nuclear medicine procedure in which a very small amount of a beta-emitting radiopharmaceutical like tin, is injected directly into a joint. The radioactive particles are taken up by synovial cells and macrophages within the inflamed synovium. This delivers localized radiation intended to reduce synovial inflammation and abnormal synovial proliferation.

The goal of RSO is not to regrow cartilage, but to decrease pain, joint effusion, and inflammation by quieting the synovium, while minimizing systemic exposure compared with oral medications. In Europe, commonly used isotopes include yttrium-90, typically for knees, rhenium-186 for medium-sized joints, and erbium-169 for small joints. These are selected based on joint size and tissue penetration characteristics.

RSO has a long history in inflammatory joint diseases such as rheumatoid arthritis and hemophilic synovitis. Much of the literature and many guidelines focus on these conditions rather than primary osteoarthritis alone. However, in clinical practice, RSO may also be considered in people with OA when synovitis and joint effusion are major drivers of pain, particularly in the knee, and when inflammation persists despite standard therapies. In these cases, the goal is not structural repair, but reduction of synovial inflammation that continues to fuel pain.

In short, RSO is a synovitis-focused tool that can be appropriate for selected OA cases, but it is not a universal OA treatment.

A typical RSO appointment varies by country and institution, but often includes confirmation that synovitis is a key contributor to symptoms using history, physical examination, and sometimes ultrasound or MRI. The radiopharmaceutical is injected into the joint using sterile technique, sometimes with image guidance. Short-term joint immobilization or activity restriction is commonly recommended to limit leakage outside the joint, and patients receive radiation-safety instructions. These are usually straightforward because the treatment is localized.

As with any procedure, proper technique and aftercare are essential. Leakage outside the joint can reduce effectiveness and increase the risk of local soft-tissue irritation.

In veterinary medicine, we apply the same biologic principle of targeting the synovium using a species-specific product and workflow. Synovetin OA is a tin-117m (Sn-117m) colloid designed for intra-articular use in dogs. Tin-117m emits conversion electrons with an extremely short tissue range, helping keep the therapeutic effect localized to the synovium. It also emits gamma photons, which allows imaging to confirm appropriate joint localization after injection.

Peer-reviewed studies in dogs with naturally occurring elbow osteoarthritis report clinically meaningful improvements in pain and function in a substantial proportion of cases. In many responders, benefits are described for approximately twelve months following a single injection. Published data also support repeat dosing in selected cases, which is important because osteoarthritis is a chronic disease and long-term management is often necessary.

There are clear similarities and differences between human radiosynoviorthesis and veterinary use. In both settings, the synovium is the therapeutic target, and the treatment is best suited for synovitis-forward osteoarthritis. The intent is to reduce inflammation and pain rather than repair cartilage. Differences include species-specific joint biomechanics, disease progression, veterinary radiation handling protocols, client instructions, and regulatory frameworks.

Osteoarthritis is a true One Health disease. Humans and animals share similar joint tissues, inflammatory mediators, pain pathways, and functional consequences of chronic joint disease. We also share the reality that OA is typically lifelong. Localized therapies that reduce inflammation without relying on continuous systemic medication are appealing across species. Human experience with radiosynoviorthesis informs safety and technique, while veterinary data offer real-world insight into durability and functional outcomes. This bidirectional learning is a clear example of One Health in action.

This post is for educational purposes only and is not medical advice. Radiosynoviorthesis and Sn-117m therapies require appropriate case selection and discussion of risks and benefits with a qualified clinician.